ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 273,80
-1,50%
Dow Jones
42 326,87
-2,58%
DAX
20 027,76
-1,15%
Brent Oil
73,155
0,58%
Bitcoin
102 414,39
2,35%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Lipella Pharmaceuticals Inc (LIPO) Cours

Lipella Pharmaceuticals Inc

Lipella Pharmaceuticals Inc (LIPO)

NASDAQ
2,61
-0,15
(-5,43%)
Fermé 19 Décembre 10:00PM
Retardé de 15 minutes
2,61
0,00
( 0,00% )
Avant marché: 10:06AM
Retardé de 15 minutes

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Statistiques et détails clés

Dernier
2,61
Prix Achat
2,40
Prix Vente
2,78
Volume échangé
-
0,00 Fourchette du Jour 0,00
2,21 Plage de 52 semaines 12,00
Cap du marché
3,155M
Clôture Veille
2,61
Ouverture
-
Dernière Transaction
Dernière heure de transaction
-
Volume financier
-
VWAP
-
Volume moyen (3 m)
908 493
Actions en circulation
1 208 919
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-0,68
Bénéfice par action (BPA)
-3,82
Chiffre d'affairess
450k
Bénéfice net
-4,62M

À propos de Lipella Pharmaceuticals Inc

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinic... Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is based in Pittsburgh, Pennsylvania. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
www.lipella.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Lipella Pharmaceuticals Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker LIPO. Le dernier cours de clôture d'Lipella Pharmaceuticals était de US$2,61. Au cours de la dernière année, les actions de Lipella Pharmaceuticals ont été négociées dans une fourchette de prix de US$ 2,21 à US$ 12,00.

Lipella Pharmaceuticals compte actuellement 1 208 919 actions en circulation. La capitalisation boursière d'Lipella Pharmaceuticals est de US$3,16 million. Lipella Pharmaceuticals a un ratio cours/bénéfice (ratio PE) de -0.68.

LIPO Dernières nouvelles

Plus de nouvelles

Form 8-K - Current report

10 Décembre 2024
Edgar (US Regulatory)

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

06 Décembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

06 Décembre 2024
Edgar (US Regulatory)

Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus

PITTSBURGH, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotechnology company dedicated to addressing serious diseases with significant unmet...

03 Décembre 2024
GlobeNewswire Inc.

Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group

PITTSBURGH, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on innovative therapies for...

21 Novembre 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

14 Novembre 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

14 Novembre 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

14 Novembre 2024
Edgar (US Regulatory)

Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform

PITTSBURGH, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases...

12 Novembre 2024
GlobeNewswire Inc.

Form 8-K - Current report

07 Novembre 2024
Edgar (US Regulatory)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.35-11.82432432432.962.982.53452722.62398903CS
40.083.162055335972.533.562.40011740582.94157817CS
12-1.07-29.07608695653.684.1442.219084933.40756724CS
26-2.47-48.62204724415.08122.2122307566.14421199CS
52-4.3628-62.56883891696.9728122.2111439796.15040453CS
156-53.55-95.352564102656.1661.762.2179806910.19654272CS
260-53.55-95.352564102656.1661.762.2179806910.19654272CS

LIPO - Frequently Asked Questions (FAQ)

What is the current Lipella Pharmaceuticals share price?
The current share price of Lipella Pharmaceuticals is US$ 2,61
How many Lipella Pharmaceuticals shares are in issue?
Lipella Pharmaceuticals has 1 208 919 shares in issue
What is the market cap of Lipella Pharmaceuticals?
The market capitalisation of Lipella Pharmaceuticals is USD 3,16M
What is the 1 year trading range for Lipella Pharmaceuticals share price?
Lipella Pharmaceuticals has traded in the range of US$ 2,21 to US$ 12,00 during the past year
What is the PE ratio of Lipella Pharmaceuticals?
The price to earnings ratio of Lipella Pharmaceuticals is -0,68
What is the cash to sales ratio of Lipella Pharmaceuticals?
The cash to sales ratio of Lipella Pharmaceuticals is 7,01
What is the reporting currency for Lipella Pharmaceuticals?
Lipella Pharmaceuticals reports financial results in USD
What is the latest annual turnover for Lipella Pharmaceuticals?
The latest annual turnover of Lipella Pharmaceuticals is USD 450k
What is the latest annual profit for Lipella Pharmaceuticals?
The latest annual profit of Lipella Pharmaceuticals is USD -4,62M
What is the registered address of Lipella Pharmaceuticals?
The registered address for Lipella Pharmaceuticals is 108 WEST 13TH STREET, WILMINGTON, DELAWARE, 19801
What is the Lipella Pharmaceuticals website address?
The website address for Lipella Pharmaceuticals is www.lipella.com
Which industry sector does Lipella Pharmaceuticals operate in?
Lipella Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
CURRCurrenc Group Inc
US$ 6,40
(220,00%)
4,75M
XHGXChange TED Inc
US$ 2,22
(194,43%)
5,73M
APCXAppTech Payments Corporation
US$ 1,02
(167,72%)
42,7M
SLXNSilexion Therapeutics Corporation
US$ 4,25
(98,60%)
1,24M
MESOMesoblast Limited
US$ 17,64
(44,00%)
84,14k
LITMSnow Lake Resources Ltd
US$ 0,4651
(-43,25%)
2,53M
AEMDAethlon Medical Inc
US$ 0,402
(-39,15%)
717,66k
MULLGranite Shares 2x Long MU Daily ETF
US$ 15,27
(-30,18%)
13,03k
MUUDirexion Daily MU Bull 2X Shares
US$ 17,51
(-28,65%)
55,07k
WAITop KingWin Ltd
US$ 0,2303
(-27,58%)
1
APCXAppTech Payments Corporation
US$ 1,02
(167,72%)
42,7M
XHGXChange TED Inc
US$ 2,22
(194,43%)
5,73M
CURRCurrenc Group Inc
US$ 6,40
(220,00%)
4,75M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0,3721
(2,00%)
3,47M
SGMOSangamo Therapeutics Inc
US$ 2,925
(24,47%)
3,3M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
LIPO
Lipella Pharmaceuticals
BIT
UI664C
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés